SAN DIEGO (USA): As medicine scratched its head on World Diabetes Day (November 14) to find surefire way to stem the tsunami of diabetes, the worm turned for stem cell therapy in USA. FDA giving GIOSTAR, a USA based stem Cell company, go ahead for phase-2 clinical trials of its stem cell therapy DT2-SCT may prove a clincher in quest for most efficacious medicine for the crippling Type II diabetes.
Stem Cell therapy, which is being hailed as future of medicine and panacea for all diseases including diabetes, gets a major shot in the arm with this nod of FDA. The American regulator of medicine has given clearance for starting Phase-2 clinical trials of ‘DT2-SCT’, a cellular therapy for Type II diabetics. The trial entails investigational new drug (IND) application. The clearance is being viewed as a turning point in the quest for effective tackling of diabetes, which is threatening to cripple the productive demographic of the world, especially that of India. GIOSTAR (Global Institute of Stem Cell Therapy and Research) based in San Diego (California) as three facilities in India, one in Bangalore, two in Ahmedabad and three in Chandigarh.
GIOSTAR has been at the forefront of stem cell research for over two decades, developing a novel cellular therapy pipeline to improve the standard of care for treating Type II diabetes patients. The Company’s novel approach using autologous mesenchymal stem cells to alleviate the disease-caused damage in diabetics offers a new hope to address the sufferings in diabetes patients without much side-effect.
DT2-SCT is a cellular therapy for Type II diabetics using autologous stem cells, isolated from the visceral tissues of the recipients, developed to target systemic ill-effects caused by diabetes-induced pathology in patients.
Diabetes is not just a disease but a global health crisis. It is estimated to affect more than one billion people worldwide. The financial burden on the global healthcare system to treat diabetes is expected to reach more than one trillion dollars annually. GIOSTAR CEO, President, and Cofounder Mr Deven Patel has stated, ‘Upon a successful completion of the clinical trials, GIOSTAR intends to make this treatment affordable to masses and poised to capture significant global market share due to GIOSTAR’s existing global infrastructure of hospitals and research centers.’
According to the Chairman and Cofounder of GIOSTAR, Dr Anand Srivastava “DT2-SCT is a cellular therapy for Type II diabetics which uses autologous stem cells, isolated from the visceral tissues of the recipients, developed to target systemic ill-effects caused by diabetes-induced pathology in patients. We are pleased to reach this milestone following extensive research and development.”
GIOSTAR expects to complete the Phase-2 clinical trial using the DT2-SCT in Type II diabetics within 12 to 18 months. It anticipates enrolling participants for the study at few sites across the United States.
